AST SpaceMobile vs. Rocket Lab: Which Space-Focused Stock Is a Better Buy in 2026?

AST SpaceMobile reported FY2025 revenue of about $70.9 million, up roughly 1,500%, but a $341.9 million net loss and nearly $1.1 billion in negative free cash flow; Rocket Lab generated about $602 million in revenue, up 38%, with a $198 million net loss and $322 million negative free cash flow. The article highlights AST’s planned 45-satellite U.S. coverage by end-2026 and Rocket Lab’s proposed $8 billion Iridium acquisition, while noting execution, funding and customer-concentration risks for both. It favors Rocket Lab as the better entry point despite high valuation, citing its more established revenue base and improving margins.

Analysis

The investable distinction is execution risk versus financing risk—not the article’s headline growth rates. ASTS has a binary deployment-to-commercialization bridge: launch cadence, usable coverage and carrier economics must convert into recurring service revenue before substantial cash consumption forces dilution or additional financing. Carrier agreements and strategic stakes may help distribution, but do not by themselves establish customer-level adoption, pricing or attractive unit economics. The stated satellite count and sales forecasts are milestones to verify, not bankable catalysts.

RKLB offers more diversified activity across launch and spacecraft systems, but its prospective upside is increasingly exposed to Neutron execution and a potentially transformative IRDM transaction. Treat the acquisition, its financing, approvals and claimed combined economics as conditional until terms and closing are confirmed; a large deal could shift the thesis from operating leverage to integration and balance-sheet risk. The reported forward P/E comparison is weak evidence when both companies are loss-making, and a standalone P/S comparison cannot establish relative cheapness.

Near term, expect event-driven volatility around launch/deployment updates and deal disclosures. Over 1–3 months, monitor ASTS satellite deployment, cash use and funding disclosures; for RKLB, monitor Neutron milestones and definitive IRDM terms. Over 6–18 months, successful service scaling or Neutron qualification could materially change the earnings base. Contrarian point: RKLB’s broader revenue base does not make it low-risk, while ASTS’s carrier relationships may support commercialization—but neither removes execution risk. Falsifiers: ASTS deployment slippage or materially worsening cash runway; RKLB Neutron delays, adverse acquisition financing, or launch/customer weakness.

Key Decisions for Investors

• Prefer RKLB over ASTS only as a relative-value, high-volatility expression: consider a small long RKLB / short ASTS pair on weakness, sized for ASTS squeeze risk. Reassess before entry if ASTS deployment data improve or RKLB acquisition terms materially worsen; avoid treating reported forward P/Es as a valuation floor.
• Do not underwrite RKLB’s claimed acquisition upside until definitive IRDM terms, financing mix, regulatory path and pro forma leverage are verified. If terms are dilutive or debt-heavy, stand aside rather than chase the strategic narrative.
• Keep ASTS on a catalyst watchlist rather than buying projected revenue: verify satellite deployment cadence, coverage quality, carrier launch timing, customer economics and cash runway. A delay or financing need would weaken the equity case; demonstrated service uptake with controlled cash burn would improve it.
• For both names, use position limits appropriate to speculative, event-sensitive equities. Revisit after the next material deployment/launch update and company filings; no broad telecom or defense hedge is warranted solely from this article.